Skip to main content
. Author manuscript; available in PMC: 2014 Sep 5.
Published in final edited form as: Sci Transl Med. 2014 Mar 5;6(226):226ra32. doi: 10.1126/scitranslmed.3008095

Figure 3. NDV and CTLA-4 blockade synergize to reject local and distant tumors.

Figure 3

(A) Treatment scheme. (B) Growth of virus-treated (right flank) B16-F10 tumors. (C) Growth of distant (left flank) B16-F10 tumors. (D) Long-term survival in the B16-F10 model. (E) Surviving animals were injected with 1×105 B16-F10 cells in right flank on day 90 and followed for survival. Data represent cumulative results from 3 experiments with n=6–11 per group. (F) Growth of virus-treated (right flank) and distant (left flank) TRAMP C2 tumors. (G) Long-term survival in the TRAMP C2 model. (H) In vitro sensitivity of B16-F10 and TRAMP C2 cells to NDV-mediated lysis at different multiplicities of infection (MOI's). (I–K) Upregulation of MHC I, MHC II, CD80, and CD86 in B16-F10 and TRAMP C2 cells infected with NDV. Representative flow cytometry plots from B16-F10 cells (I) and calculated average median fluorescent intensities (MFI) for B16-F10 (J) and TRAMP C2 (K) cells are shown. Mean +/− SEM is shown. Data represent results from 1 of 3 (B–E), or 1 of 2 (F,G) independent experiments with n=5–10 per group. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.